Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione
Z Chen, PA Vigueira, KT Chambers, AM Hall… - Journal of Biological …, 2012 - ASBMB
Currently approved thiazolidinediones (TZDs) are effective insulin-sensitizing drugs that
may have efficacy for treatment of a variety of metabolic and inflammatory diseases, but their
use is limited by side effects that are mediated through ectopic activation of the peroxisome
proliferator-activated receptor γ (PPARγ). Emerging evidence suggests that the potent anti-
diabetic efficacy of TZDs can be separated from the ability to serve as ligands for PPARγ. A
novel TZD analog (MSDC-0602) with very low affinity for binding and activation of PPARγ …
may have efficacy for treatment of a variety of metabolic and inflammatory diseases, but their
use is limited by side effects that are mediated through ectopic activation of the peroxisome
proliferator-activated receptor γ (PPARγ). Emerging evidence suggests that the potent anti-
diabetic efficacy of TZDs can be separated from the ability to serve as ligands for PPARγ. A
novel TZD analog (MSDC-0602) with very low affinity for binding and activation of PPARγ …
